Provide professional treatment informations for patients with liver cirrhosis.
»Home | »Sitemap | »Contact us | »news
HomeTreatment in cirrhosis(HBV-related)

Treatment in cirrhosis(HBV-related)

Liver cirrhosis is common result of hepatitis B virus (HBV) infection. Many HBV patients (about 7%) will develop cirrhosis. Antiviral treatment with NUCs"nucleos(t)ide analogues" can prevent the procession of cirrhosis with chronic HBV infection and hepatic decompensation.

Antiviral treatment is to improve hepatic dysfunction, and decrease in inflammatory activity to stop HBV-associated liver injury. In order to suppress HBV replication to undetectable levels, Antiviral treatment should therefore be started as soon as possible.
Today, tolerable nucleos(t)ide analogues have been successfully used in clinical, the use of interferon is contraindicated in these patients . The NUCs: lamivudine (LAM), telbivudine (LdT), entecavir (ETV), adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF) have been approved for the treatment of HBV patients with and without cirrhosis. Long-term treatment with NUCs can delay the progression of fibrosis, and can restore liver function in many patients, and the rate of hepatic decompensation is significantly decreased. Because the effective treatments, many patients on the waiting list for liver transplantation has significantly decreased.
As a nucleoside analogue, Lamivudine(LAM) has been used for which the most clinical experience exists in patients with cirrhosis. It can improve and survival biochemical function of the liver, and improves recovery of liver function in patients with HBV-related decompensated cirrhosis.
NUCs treatment have the general safety and tolerability in patients with decompensated cirrhosis, but as a decrease in renal function is more frequently observed, the use of ADV should be avoided in patients with decompensated cirrhosis. Patients with decompensated cirrhosis have a general risk in Lactic acidosis; so lactate levels should be monitored undergoing antiviral treatment.
NUC treatment in patients with cirrhosis should be began as early as possible for complete suppression of HBV replication.

Related articles

YHK effective: Fatty Liver(NASH)

YHK:Inhibitory effect for the liver cancerous

YHK effective: the treatment of Hepatitis C

Anti-fibrotic(liver) effect of YHK

What's YHK

About Liver Cirrhosis

Eight Causes of Liver Cirrhosis

Antifibrotic treatment is the last line of defense to prevent liver cirrhosis.

  • Liver dysfunction
  • liver cirrhosis, NASH, fatty liver, hepatitis
  • Patients with liver diseases troubled by the side effects of drugs
I was infected with hepatitis C and then it developed to liver cirrhosis.I started to take YHK in 2006, after one week, my ALT and AST values began to decrease. In Dec, I stopped the injection treatment.YHK help me a lot..
I’m a liver cirrhosis patient. I was hospitalized three times within three years and the doctor told me that the prognosis was bad.Then my friend strongly recommended me to take YHK. After taking YHK, my liver function turned better, and the jaundice disappeared as well.
and more.... »
Copyright ⓒ 2014 All Rights Reserved